The prevalence of metabolic syndrome in different ethnic groups in Turkey.

OBJECTIVE: To determine the prevalence of metabolic syndrome and its risk factors in various ethnic groups in Istanbul, Turkey. METHODS: Study participants were aged ≥ 20 years. Risk factor components for metabolic syndrome were measured and its presence was determined in study participants. RESULTS: The study included 254 Greeks, 273 West Thracians, 275 East Turkistanis and 304 Armenians. The prevalence of metabolic syndrome was significantly different between groups (Greeks, 19.3%; West Thracians, 24.9%; East Turkistanis, 15.3%; Armenians, 20.4%), and increased with age in all groups. Low levels of high-density lipoprotein cholesterol (HDL-C) were found mainly in Greeks (females, 64.5%; males, 61.6%) and West Thracians (females, 75.8%; males, 73.1%). Among East Turkistanis, HDL-C and triglyceride levels were significantly higher compared with the other ethnic groups. Hypertension was the most frequently encountered component of metabolic syndrome in East Turkistanis. CONCLUSIONS: The prevalence of metabolic syndrome varied between ethnic groups living in the same geographical location. In Turkey, metabolic syndrome is common. It is important to determine differences between ethnic groups, as this will assist in identifying those at higher risk of developing coronary heart disease.

Safety of peginterferon alfa-2a (40KD) treatment in patients with chronic hepatitis B infection: an observational, multicenter, open label, non-interventional study in Turkish patients.

BACKGROUND/AIMS: Pegylated alfa interferon is the only immunomodulatory drug licensed for hepatitis B. We evaluated the safety and tolerability of peginterferon alfa-2a (40KD) in patients with chronic hepatitis B. MATERIALS AND METHODS: A total of 113 chronic hepatitis B patients under peginterferon alfa-2a (40KD; 180 µg/week) treatment were included in this multicenter, open label, non-interventional study, and 66 patients completed the follow-up period. Vital signs, physical examination and laboratory findings, concomitant medications, and adverse events were recorded. A Quality of Life questionnaire (Short Form-36) was performed twice, at the beginning and at the end of the study. RESULTS: There was no significant difference between initial and last visits in terms of physical examination findings and Short Form-36 scores. A total of 27 adverse events were reported in 15 patients (22.7%), with most of them being mild in intensity (70.4%). The rates of the adverse events were similar in the monotherapy and combination therapy groups (peginterferon alfa-2a + lamivudine, peginterferon alfa-2a + adefovir or peginterferon alfa-2a + entecavir therapy groups), at 23.7% and 14.3%, respectively. The dosage of peginterferon had to be reduced in 3 patients (4.5%) due to thrombocytopenia. Overall patient compliance to treatment was detected as 85.9%. CONCLUSIONS: Based on the lack of serious adverse events and absence of impairment in Quality of Life, peginterferon alfa-2a (40KD, 180 µg/week, subcutaneously) treatment for 48 weeks led to a high level of patient compliance and was associated with a high degree of safety and tolerability for the treatment of adult patients with chronic hepatitis B in real-life practice.

Utility of diffusion-weighted MRI for assessing liver fibrosis in patients with chronic active hepatitis.

PURPOSE: We evaluated the utility of quantitative diffusion-weighted magnetic resonance imaging (DW-MRI) for assessing both the relationship between the degree of fibrosis and the histological activity index (HAI) in chronic hepatitis (CH) cases and attempted to determine whether the apparent diffusion coefficient value (ADC) could be used as a reference for the degree of fibrosis detected by histology. MATERIALS AND METHODS: The study population consisted of 55 CH patients (Group I) and a control group of 30 volunteers (Group II). Group I consisted of 31 CH-B (CHB), 18 CH-C (CHC) and 6 non-alcoholic steatohepatitis patients. DW-MRI of the liver with b values of 0, 500 and 1000 s/mm(2) was performed, and liver biopsies of the patients were obtained two weeks later. The ADC value, degree of liver fibrosis and HAI were compared within Group I, and the ADC values of both groups were compared with each other. RESULTS: The ADC was lower in Group I than in Group II (P < 0.05). The ADC of the left lobe lateral (LL) (P < 0.05), left lobe medial (LM) and right lobe anterior (RA) segments (P < 0.01) in Group I were lower than those of Group II. There was no relationship between HAI and the ADC of LL, LM, RA and right lobe posterior (RP) segments in Group I. Additionally, there was no correlation between fibrosis scores and ADC in Group I, whereas there was a negative correlation between fibrosis scores and ADC values of the LL (28.3%) and RP (29.5%). CONCLUSION: CH patients had lower ADC values. There was no correlation between ADC values and fibrosis stages or ADC and HAI values. Quantitative DW-MRI was not useful in determining the degree of fibrosis in liver tissue.

The prevalence of dermatologic manifestations related to chronic hepatitis C virus infection in a study from a single center in Turkey.

BACKGROUND: Chronic hepatitis C virus (HCV) infection may be associated with many dermatologic manifestations. The aim of this study was to determine the prevalence of dermatologic manifestations related to chronic HCV infection in Turkey. MATERIALS AND METHODS: 70 patients with chronic HCV infection and 70 healthy volunteers were investigated. They were carefully questioned and skin, mucosa, hair and nails were systematically examined. Laboratory tests for the serum levels of aspartate aminotransferase, alanine aminotransferase, gamma glutamyl transpeptidase, bilirubine and rheumatoid factor were done in all of them. RESULTS: The only symptom which was more frequent in patients with chronic HCV infection was generalized pruritus (13 cases, 18.57%). It was observed in three cases of the control group (4.28%), the difference being statistically significant (p:0.01). In the group of patients with chronic HCV infection, three patients were diagnosed as leukocytoclastic vasculitis and three as lichen planus (4.28%). Neither leukocytoclastic vasculitis nor lichen planus was observed in the control group. CONCLUSION: In our patients, an association between HCV infection and pruritus was found. The patients with unexplained pruritus should be investigated for HCV infection. Leukocytoclastic vasculitis and lichen planus were not observed frequently enough to reach statistical significance (p:0.24).